Rapid post-acquisition integration delivers $100m topline growth for a PE-backed Specialty Pharma

Vision

The value creation plan for a PE-backed European specialty pharma included inorganic topline growth through a $100M acquisition of 15 products across 50 countries. Post-deal success depended on fast-tracking execution—integrating the portfolio, enabling marketing authorization transfers (MATs), and transferring and scaling TechOps and Commercial operations.

Challenge

• The company had never managed an integration of this size, speed,
and cross-functional complexity. 
• Relationship and project management of the transfer had to be robust for smooth and swift execution.
• Commercial strategy needed to engage 20 affiliate partners to 
protect the existing topline while assessing the landscape for new trajectories for revenue growth.

Solution

The company partnered with Genioo to fast-track product integration and get to legal day 1 readiness. We set up a cross-functional, co-led Value Realization Office (VRO) to project manage the post-merger integration and find new sources of value. 

The VRO combined the best of the portfolio company with Genioo experts in PMI, strategic market assessment, portfolio optimization, technical transfers, and supply chain and commercial scale up. In three months, together with the SteerCo and workstreams, we aligned on the priorities, co-created detailed action plans, and executed in three core areas:

1. Marketing & Commercial – Engaged existing affiliates and secured the topline. Assessed the market landscape and segmented the portfolio to define a commercial strategy aligning existing and new territories with the right products and pricing structure.
2. Technical transfers – Partnered with TechOps and Procurement to transfer stock, packaging, and artwork. Conducted a cost of goods (COGS) analysis to leverage global operations and process standardization and renegotiate production and distribution agreements. 
3. R&D and Regulatory – Readiness for legal day 1 including market authorization transfers and all supporting clinical trial, PV & safety, and medical data and documentation. 

We worked as One Team across the VRO, workstreams, and the divestment partner (a top 10 global pharma) to smooth the transfer. And robust governance provided a platform for full transparency and fast decision escalation. 

Impact

• Successful post-acquisition integration and value capture from 15 products across 50 countries.
• Seamless PMI/PMO execution and workstream support enabled an additional $100m top-line and double the expected bottom-line improvements.
• Local pricing strategies and COGS improvements enabled an additional 15% improvement on target margins. 
• The company is well positioned and prepared for future divestments and growth opportunities.